SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
-3.38%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$213M
AUM Growth
+$213M
(+100,917%)
Cap. Flow
+$58.2M
Cap. Flow
% of AUM
27.29%
Top 10 Holdings %
Top 10 Hldgs %
50.55%
Holding
88
New
13
Increased
29
Reduced
15
Closed
19
Top Buys
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.59M |
| 2 |
Veracyte
VCYT
|
$5.84M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$5.28M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$4.85M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$4M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$11.1M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$5.19M |
| 3 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$1.44M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$1.03M |
| 5 |
Immatics
IMTX
|
$786K |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
1
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.9M | 5.52% | 313,962 +5,143 | +2% | +$294K |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $14.4M | 4.45% | 1,562,957 +327,173 | +26% | +$3.02M |
|
|
3
Veracyte
VCYT
$2.39B
| $14.3M | 4.4% | 718,789 +293,235 | +69% | +$5.84M |
|
4
Cerus
CERS
$251M
| $11.1M | 3.41% | 2,093,861 +695,461 | +50% | +$3.68M |
|
5
Merus
MRUS
$4.98B
| $10.6M | 3.27% | 469,113 +144,394 | +44% | +$3.27M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $9.09M | 2.8% | 418,660 +349,951 | +509% | +$7.59M |
|
|
CTIC
7
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $8.24M | 2.54% | 1,380,111 -869,889 | -39% | -$5.19M |
|
8
Aclaris Therapeutics
ACRS
$209M
| $7.53M | 2.32% | 539,545 +264,212 | +96% | +$3.69M |
|
9
Cogent Biosciences
COGT
$1.69B
| $7.41M | 2.28% | 820,954 +247,255 | +43% | +$2.23M |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.22M | 2.22% | 40,787 +29,831 | +272% | +$5.28M |
|
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $7.08M | 2.18% | 232,630 +131,549 | +130% | +$4M |
|
12
Krystal Biotech
KRYS
$4.27B
| $6.91M | 2.13% | 105,277 +58,788 | +126% | +$3.86M |
|
13
Apellis Pharmaceuticals
APLS
$3.48B
| $5.87M | 1.81% | 129,795 +24,427 | +23% | +$1.1M |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.76M | 1.77% | 72,187 +4,745 | +7% | +$378K |
|
|
15
Oric Pharmaceuticals
ORIC
$994M
| $4.85M | 1.49% | +1,082,304 | New | +$4.85M |
|
16
Biogen
BIIB
$19.4B
| $4.25M | 1.31% | 20,825 +10,577 | +103% | +$2.16M |
|
17
Insmed
INSM
$28.8B
| $4.19M | 1.29% | 212,482 +110,415 | +108% | +$2.18M |
|
18
Mersana Therapeutics
MRSN
$36.5M
| $3.93M | 1.21% | +850,000 | New | +$3.93M |
|
|
APEN
19
DELISTED
Apollo Endosurgery, Inc.
APEN
| $3.92M | 1.21% | 1,074,879 +70,480 | +7% | +$257K |
|
|
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.84M | 1.18% | 26,374 -76,123 | -74% | -$11.1M |
|
21
United Therapeutics
UTHR
$13.8B
| $3.82M | 1.18% | 16,227 +1,391 | +9% | +$328K |
|
|
22
Immatics
IMTX
$619M
| $3.09M | 0.95% | 355,103 -90,231 | -20% | -$786K |
|
23
Vertex Pharmaceuticals
VRTX
$100B
| $2.94M | 0.9% | 10,414 +2,776 | +36% | +$782K |
|
24
Cullinan Oncology
CGEM
$445M
| $2.73M | 0.84% | +213,090 | New | +$2.73M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.6M | 0.8% | 139,539 +25,535 | +22% | +$476K |
|